Strategy for selecting nanotechnology carriers to overcome immunological and hematological toxicities challenging clinical translation of nucleic acid-based therapeutics.
about
Current understanding of interactions between nanoparticles and the immune systemCritical questions in development of targeted nanoparticle therapeuticsAdvances in the use of nanocarriers for cancer diagnosis and treatmentPre-clinical immunotoxicity studies of nanotechnology-formulated drugs: Challenges, considerations and strategyHDL as a drug and nucleic acid delivery vehicleThe impact of nanoparticle protein corona on cytotoxicity, immunotoxicity and target drug deliveryIntracellular Delivery by Shape Anisotropic Magnetic Particle-Induced Cell Membrane Cuts.
P2860
Q26345204-93C37D6D-7F81-4D22-AA5F-2A81D696944DQ26751896-11878FCE-35BD-41D1-A0C3-C940C99ABF04Q28070065-0B5A6F4D-6E58-4751-AF0A-023FE2677876Q28081577-0A08C73F-959D-41F2-BD0E-762C1049E427Q28083209-F2AE48B2-39AF-44D7-B3C3-FDB3321B0953Q28085280-DAEF9668-6686-46AC-BBAD-F3E9F90A6C57Q45883228-0ACB5BDB-AD69-44AB-A70D-CCAAFD39A199
P2860
Strategy for selecting nanotechnology carriers to overcome immunological and hematological toxicities challenging clinical translation of nucleic acid-based therapeutics.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Strategy for selecting nanotec ...... cleic acid-based therapeutics.
@en
type
label
Strategy for selecting nanotec ...... cleic acid-based therapeutics.
@en
prefLabel
Strategy for selecting nanotec ...... cleic acid-based therapeutics.
@en
P2860
P1476
Strategy for selecting nanotec ...... cleic acid-based therapeutics.
@en
P2093
Marina A Dobrovolskaia
Scott E McNeil
P2860
P304
P356
10.1517/17425247.2015.1042857
P407
P577
2015-05-20T00:00:00Z